References
- Musher DM. Streptococcus pneumoniae. In: Mandell GL, editor. Principles. and practice of infectious diseases. Churchill Livingstone Elsevier; Philadelphia, PA, USA: 2010. p. 2623-42
- Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging 1999;15(Suppl 1):21-30
- Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009;30(2):189-209
- Prato R, Tafuri S, Fortunato F, Martinelli D. Why it is still important that countries know the burden of pneumococcal disease. Hum Vaccin 2010;6(11):918-21
- 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83(42):373-84
- Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10)):760-8
- Pneumococcal Awareness. Fact sheet: don’t underestimate pneumococcal disease (2011). Available from: www.pneumo.co.uk/Portals/0/pdf/Factsheet_Download2.pdf [Last accessed 27 December 2012]
- Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002;161(4):188-95
- Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 1999;17(Suppl 1):S79-84
- Pebody RG, Leino T, Nohynek H, et al. Pneumococcal vaccination policy in Europe. Euro Surveill 2005;10(9):174-8
- European Medicines Agency. Summary of product characteristics: Pneumovax II (2011). Available from: www.medicines.org.uk/EMC/medicine/1446/SPC [Last accessed 7 December 2012]
- Pneumococcal. In: Salisbury D, editor. Immunisation against infectious disease (the green book). The Stationery Office; London, UK: 2012. p. 295-313
- Spindler C, Hedlund J, Jasir A, et al. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine 2008;26(43):5541-6
- Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008(1):CD000422
- Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008;46(7):1093-100
- Mooney JD, Weir A, McMenamin J, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 2008;8:53
- Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010;28(43):7063-9
- Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010;340:c1004
- Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012;30(48):6802-8
- Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin Infect Dis 2001;33(12):2078-9
- Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000;31(2):444-50
- Sisk JE, Whang W, Butler JC, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138(12):960-8
- Evers SM, Ament AJ, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007;26(8):531-40
- Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008;26(11):1420-31
- Ogilvie I, Khoury AE, Cui Y, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 2009;27(36):4891-904
- Smith KJ, Lee BY, Nowalk MP, et al. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine 2010;28(48):7620-5
- Fedson DS, Nicolas-Spony L, Klemets P, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011;10(8):1143-67
- Akin L, Kaya M, Altinel S, Durand L. Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey. Hum Vaccin 2011;7(4):441-50
- Jiang Y, Gauthier A, Annemans L, et al. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Rev Pharmacoecon Outcomes Res 2012;12(5):645-60
- European Medicines Agency. Summary of product characteristics: Prevenar (2012). Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000323/WC500041563.pdf [Last accessed 7 December 2012]
- European Medicines Agency. Summary of product characteristics: Prevenar 13 (2013). Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf [Last accessed 7 December 2012]
- Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR-11):1-18
- European Medicines Agency. Summary of product characteristics: Synflorix (2012). Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf [Last accessed 7 December 2012]
- Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41
- van der Linden M, Imohl M. R2762 Serotype distribution among bacteraemic pneumococcal pneumonia in adults in Germany. Clin Microbiol Infect 2011;17(Suppl 4):S832
- Ardanuy C, Domenech A, Rolo D, et al. Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008). J Antimicrob Chemother 2010;65(4):634-43
- Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Rev Vaccines 2012;11(8):889-902
- Jiang Y, Gauthier A, Annemans L, et al. A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany. Expert Rev Pharmacoecon Outcomes Res 2012;12(5):631-43
- Jiang Y, Gauthier A, Keeping S, Carroll S. Cost–effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res 2014;14(6). In press
- Health Protection Agency. Current epidemiology of invasive pneumococcal disease (IPD) (2012). Available from: www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/ [Last accessed 7 December 2012]
- van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65(1):17-24
- Trotter CL, Waight P, Andrews NJ, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect 2010;60(3):200-8
- Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect 2010;61(2):114-24
- Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012;67(6):540-5
- Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl 3):iii1-55
- Office for National Statistics. National population projections, 2010-based projections (2011). Available from: www.ons.gov.uk/ons/rel/npp/national-population-projections/2010-based-projections/index.html [Last accessed 7 December 2012]
- Office for National Statistics. Historic and projected mortality data (1951 to 2060) from the UK life tables, 2010-based (2012). Available from: http://ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-257453 [Last accessed 7 December 2012]
- Begum F, Pebody R. Pneumococcal polysaccharide vaccine (PPV) uptake report (2012). Available from: http://immunisation.dh.gov.uk/ppv-uptake-report-29-feb-2012/ [Last accessed 7 December 2012]
- Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011;52(5):633-40
- Ridda I, Musher DM. Is there a potential role for protein-conjugate pneumococcal vaccine in older adults? Australas Med J 2012;5(4):231-5
- Fedson DS, Guppy MJ. Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother 2013;9(6):1382-4
- Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006;43(7):860-8
- Middleton DB, Lin CJ, Smith KJ, et al. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Infect Control Hosp Epidemiol 2008;29(5):385-94
- Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325(21):1453-60
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal (2008). Available from: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Last accessed 7 December 2012]
- British National Formulary. British National Formulary 63 (2012). Available from: www.bnf.org [Last accessed 7 December 2012]
- Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine 2012;30(23):3459-62
- Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002;324(7341):809
- Department of Health. NHS Reference Cost 2010/11 (2011). Available from: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_131140 [Last accessed 7 December 2012]
- Curtis L. Unit costs of health and social care 2011. 2011. Available from: www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf [Last accessed 7 December 2012]
- Department of Health. 2003-04 to 2010-11 programme budgeting data (2012). Available from: www.dh.gov.uk/health/2012/08/programme-budgeting-data/ [Last accessed 27 December 2012]
- ClinicalTrials.gov. Study evaluating a 13-valent pneumococcal conjugate vaccine (13vPnC) in adults (CAPITA) (2012). Available from: http://clinicaltrials.gov/ct2/show/NCT00744263 [Last accessed 7 December 2012]
- Bonten M, Bolkenbaas M, Huijts S, et al. Community acquired pneumonia immunisation trial in adults (CAPITA). Presented at 9th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); Hyderabad, India, 9-13 March 2014. Available from: http://isppd.meetingxpert.net/ISPPD_433/poster_90453/program.aspx/anchor90453 [Last accessed 24 March 2014]
- Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis 2014;58(6):854-64
- Health Protection Agency. Frequently asked questions about pneumococcal vaccine (2012). Available from: www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/GuidelinesPneumococcal/pneumoFAQs/ [Last accessed 7 December 2012]
- McIntosh ED, Conway P, Willingham J, et al. Pneumococcal pneumonia in the UK–how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 2005;23(14):1739-45
- Mangtani P, Roberts JA, Hall AJ, Cutts FT. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Int J Epidemiol 2005;34(3):565-74